Authorities in India have seized counterfeit Mounjaro pens valued at nearly ₹7 million (around $84,000 USD) during an operation conducted by the Haryana Food and Drug Control Administration on April 19, 2026. The counterfeit drugs, which are part of the GLP-1 receptor agonist category, have surged in popularity for weight management and diabetes treatment since their launch in India in 2025. The operation revealed that the fake pens were sold online at a 27% discount compared to genuine products, raising serious safety concerns as they were not stored under proper refrigeration. Consumers are advised to check packaging closely, verify the source of medications, and inspect storage conditions to avoid counterfeit drugs. Eli Lilly, the manufacturer of Mounjaro, is cooperating with authorities to ensure patient safety. With the Indian weight-loss drug market expected to reach ₹80 billion by 2030, vigilance against counterfeit medications is essential to protect public health.